Exosomes - Pipeline Insight, 2022
This report can be delivered to the clients within 2-3 Business Days
DelveInsight’s, “Exosomes - Pipeline Insight, 2022” report provides comprehensive insights about 55+ companies and 70+ pipeline drugs in Exosomes pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Exosomes: Overview
Exosomes are a type of extracellular vesicle, a family of nanometer-scale, biomolecule-filled, lipid-wrapped packages that contain constituents (protein, DNA, and RNA) of the cells that secrete them. Exosomes can be a highly heterogeneous population and have distinct abilities to induce a complex biological response. Exosomes are isolated from a wide spectrum of biological fluids, including blood, urine, saliva and breast milk. Exosomes are generated in a process that involves double invagination of the plasma membrane and the formation of intracellular multivesicular bodies containing intraluminal vesicles. Exosomes are associated with immune responses, viral pathogenicity, pregnancy, cardiovascular diseases, central nervous system-related diseases, and cancer progression. Exosomes have therapeutic potential to control many diseases, along with aid in disease diagnosis. Extensive studies are going on for the role of exosomes in the diagnosis and treatment of various pathologies.
Report Highlights
This segment of the Exosomes report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Exosomes Emerging Drugs
Further product details are provided in the report……..
Exosomes: Therapeutic Assessment
This segment of the report provides insights about the different Exosomes drugs segregated based on following parameters that define the scope of the report, such as:
Exosomes: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Exosomes therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Exosomes drugs.
Exosomes Report Insights
Current Scenario and Emerging Therapies:
DelveInsight’s, “Exosomes - Pipeline Insight, 2022” report provides comprehensive insights about 55+ companies and 70+ pipeline drugs in Exosomes pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Exosomes: Overview
Exosomes are a type of extracellular vesicle, a family of nanometer-scale, biomolecule-filled, lipid-wrapped packages that contain constituents (protein, DNA, and RNA) of the cells that secrete them. Exosomes can be a highly heterogeneous population and have distinct abilities to induce a complex biological response. Exosomes are isolated from a wide spectrum of biological fluids, including blood, urine, saliva and breast milk. Exosomes are generated in a process that involves double invagination of the plasma membrane and the formation of intracellular multivesicular bodies containing intraluminal vesicles. Exosomes are associated with immune responses, viral pathogenicity, pregnancy, cardiovascular diseases, central nervous system-related diseases, and cancer progression. Exosomes have therapeutic potential to control many diseases, along with aid in disease diagnosis. Extensive studies are going on for the role of exosomes in the diagnosis and treatment of various pathologies.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Exosomes R&D. The therapies under development are focused on novel approaches for Exosomes.
This segment of the Exosomes report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Exosomes Emerging Drugs
- ExoFlo: Direct Biologics
- Progenza: Regeneus
Further product details are provided in the report……..
Exosomes: Therapeutic Assessment
This segment of the report provides insights about the different Exosomes drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players working on Exosomes
- Phases
- Late-stage products (Phase III and
- Mid-stage products (Phase II and
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Infusion
- Intradermal
- Intramuscular
- Intranasal
- Intravaginal
- Oral
- Parenteral
- Subcutaneous
- Topical
- Molecule Type
- Vaccines
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Product Type
Exosomes: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Exosomes therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Exosomes drugs.
Exosomes Report Insights
- Exosomes Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Scenario and Emerging Therapies:
- How many companies are developing Exosomes drugs?
- How many Exosomes drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for Exosomes?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Exosomes therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Exosomes and their status?
- What are the key designations that have been granted to the emerging drugs?
- Direct Biologics
- Capricor
- Regeneus
- AVEM HealthCare
- Aegle Therapeutics
- Organicell Regenerative Medicine
- Codiak Biosciences
- United Therapeutics
- ArunA Biomedical
- Evox Therapeutics
- ArunA Biomedical
- MolecuVax
- Versatope Therapeutics
- Lamellar Biomedical
- Azymus Therapeutics
- Alxerion Biotech
- Avalon GloboCare
- Capricor Therapeutics
- ExoFlo
- CAP-1002
- Progenza
- Mesenchymal stem cells (MSCs) exosomes
- AGLE 102
- Zofin
- exoIL-12
- exoSTING
- UNEX 42
- AB 126
- EVX-102
- AB 127
- EVX-101
- AB 128
- MVAX 001
- VT 105
- IPF-Lamellasome
- Muco-ease
- AZ-001
- ALX-029
- ALX-102
- AVA-201
- CAP 2003
- AVA 203
Introduction
Executive Summary
Exosomes: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Late Stage Products (Phase III)
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
ExoFlo: Direct Biologics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
UNEX 42: United Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
EVX-102: Evox Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Exosomes Key Companies
Exosomes Key Products
Exosomes- Unmet Needs
Exosomes- Market Drivers and Barriers
Exosomes- Future Perspectives and Conclusion
Exosomes Analyst Views
Exosomes Key Companies
Appendix
Executive Summary
Exosomes: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Late Stage Products (Phase III)
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
ExoFlo: Direct Biologics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
UNEX 42: United Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
EVX-102: Evox Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Exosomes Key Companies
Exosomes Key Products
Exosomes- Unmet Needs
Exosomes- Market Drivers and Barriers
Exosomes- Future Perspectives and Conclusion
Exosomes Analyst Views
Exosomes Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Exosomes
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Exosomes
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Exosomes
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Exosomes
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
